Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

72.57 -0.30 (-0.41%)
Streaming Delayed Price Updated: 9:50 AM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
3 Cash-Producing Stocks That Concern Us
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) Embodies the "Affordable Growth" Investment Strategy
Discover Corcept Therapeutics (CORT), an affordable growth stock with strong revenue growth, high profitability, and a compelling valuation within the pharmaceuticals sector. 
Via Chartmill
Corcept Therapeutics Inc (NASDAQ:CORT): A Strong Growth Stock with Solid Fundamentals and Technical Upside
Corcept Therapeutics (CORT) shows strong growth, profitability, and technical momentum, making it a top pick for investors seeking high-potential stocks. 
Via Chartmill
Earnings Scheduled For July 31, 2025
 
Via Benzinga
3 Cash-Heavy Stocks with Warning Signs
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining... 
Via StockStory
CORT Q2 Deep Dive: Product Supply Constraints and Pipeline Progress Reshape Outlook
Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 18.7% year on year to $194.4 million. The company’s full-year revenue... 
Via StockStory
2 Growth Stocks Set to Flourishand 1 We Avoid
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle. 
Via StockStory
3 Low-Volatility Stocks That Fall Short
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
 
Via Benzinga
Corcept (NASDAQ:CORT) Misses Q2 Sales Targets
Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 18.7% year on year to $194.4 million. The company’s full-year revenue... 
Via StockStory
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Business Wire
CORCEPT THERAPEUTICS INC (NASDAQ:CORT): A Strong Affordable Growth Pick with Solid Fundamentals
CORCEPT THERAPEUTICS (CORT) offers strong growth potential with fair valuations, solid profitability, and a healthy balance sheet, making it an attractive pick for Affordable Growth investors. 
Via Chartmill
What To Expect From Corcept’s (CORT) Q2 Earnings
Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be reporting earnings this Thursday after the bell. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) – A Strong Growth Stock with Technical Breakout Potential
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) shows strong revenue growth, high profitability, and a promising technical setup, making it a noteworthy candidate for growth investors. 
Via Chartmill
Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years
 
Via Benzinga
agilon health, LifeStance Health Group, The Pennant Group, Corcept, and Amphastar Pharmaceuticals Shares Plummet, What You Need To Know
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like... 
Via StockStory
Topics Lawsuit World Trade
What's Driving the Market Sentiment Around Corcept Therapeutics?
 
Via Benzinga
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
3 High-Flying Stocks Skating on Thin Ice
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated... 
Via StockStory
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - A Promising Affordable Growth Stock
CORCEPT THERAPEUTICS (NASDAQ:CORT) offers strong growth, solid profitability, and reasonable valuation, making it an interesting candidate for investors seeking affordable growth stocks. 
Via Chartmill
1 Cash-Producing Stock Worth Your Attention and 2 to Ignore
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
Here's How Much $100 Invested In Corcept Therapeutics 20 Years Ago Would Be Worth Today
 
Via Benzinga
3 Russell 2000 Stocks in Hot Water
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
Via StockStory
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) – A Strong Growth Stock with Technical Breakout Potential
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) shows strong growth fundamentals and a bullish technical setup, making it a candidate for growth investors. High revenue growth, profitability, and a debt-free... 
Via Chartmill
Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85th Scientific Sessions with Simultaneous Publication in Diabetes Care
From Corcept Therapeutics Incorporated
Via Business Wire
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study
Corcept's ALS drug dazucorilant improved survival despite missing the main goal; ovarian cancer drug combo met its target in Phase 3. 
Via Benzinga
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
From Corcept Therapeutics Incorporated
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.